NO971991L - Heterosyklus-substituerte propensyrederivater som NMDA-antagonister - Google Patents

Heterosyklus-substituerte propensyrederivater som NMDA-antagonister

Info

Publication number
NO971991L
NO971991L NO971991A NO971991A NO971991L NO 971991 L NO971991 L NO 971991L NO 971991 A NO971991 A NO 971991A NO 971991 A NO971991 A NO 971991A NO 971991 L NO971991 L NO 971991L
Authority
NO
Norway
Prior art keywords
acid derivatives
propenoic acid
heterocycle
nmda antagonists
substituted propenoic
Prior art date
Application number
NO971991A
Other languages
English (en)
Other versions
NO971991D0 (no
NO313197B1 (no
Inventor
Boyd Lynn Harrison
Philip Lee Nyce
Robert Allan Farr
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of NO971991D0 publication Critical patent/NO971991D0/no
Publication of NO971991L publication Critical patent/NO971991L/no
Publication of NO313197B1 publication Critical patent/NO313197B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
NO19971991A 1994-10-31 1997-04-29 Heterosyklus-substituerte propensyrederivater som NMDA- antagonister NO313197B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08332016 US5563157B1 (en) 1994-10-31 1994-10-31 Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
PCT/US1995/012085 WO1996013501A1 (en) 1994-10-31 1995-09-21 Heterocycle substituted propenoic acid derivatives as nmda antagonists

Publications (3)

Publication Number Publication Date
NO971991D0 NO971991D0 (no) 1997-04-29
NO971991L true NO971991L (no) 1997-04-29
NO313197B1 NO313197B1 (no) 2002-08-26

Family

ID=23296353

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971991A NO313197B1 (no) 1994-10-31 1997-04-29 Heterosyklus-substituerte propensyrederivater som NMDA- antagonister

Country Status (21)

Country Link
US (3) US5563157B1 (no)
EP (1) EP0790994B1 (no)
JP (1) JP3934678B2 (no)
KR (1) KR100401138B1 (no)
CN (1) CN1068001C (no)
AT (1) ATE217307T1 (no)
AU (1) AU696423B2 (no)
CA (1) CA2202992C (no)
DE (1) DE69526668T2 (no)
DK (1) DK0790994T3 (no)
ES (1) ES2173198T3 (no)
FI (1) FI971831A0 (no)
HU (1) HU222372B1 (no)
IL (1) IL115791A (no)
MX (1) MX9703146A (no)
NO (1) NO313197B1 (no)
NZ (1) NZ293842A (no)
PT (1) PT790994E (no)
TW (1) TW336232B (no)
WO (1) WO1996013501A1 (no)
ZA (1) ZA959046B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
IL154981A0 (en) 2000-10-10 2003-10-31 Smithkline Beecham Corp Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー ユニバーシティ pHに依存するNMDAレセプターアンタゴニスト
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 nmda 수용체 길항물질

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU216787B (hu) * 1990-07-16 1999-08-30 Merrell Dow Pharmaceuticals Inc. Eljárás excitátoros aminosav-antagonista hatású indolszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
JP3094450B2 (ja) * 1990-10-15 2000-10-03 アストラゼネカ・アクチエボラーグ 神経保護特性を有するピペリジン誘導体
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
WO1994027964A1 (en) * 1993-05-27 1994-12-08 Merrell Dow Pharmaceuticals Inc. 3-(indol-3-yl) propenoic acid derivatives and as nmda antagonists

Also Published As

Publication number Publication date
ATE217307T1 (de) 2002-05-15
TW336232B (en) 1998-07-11
EP0790994A1 (en) 1997-08-27
DE69526668D1 (de) 2002-06-13
ZA959046B (en) 1996-05-17
US5563157B1 (en) 1999-02-02
NO971991D0 (no) 1997-04-29
WO1996013501A1 (en) 1996-05-09
EP0790994B1 (en) 2002-05-08
HU222372B1 (hu) 2003-06-28
KR100401138B1 (ko) 2003-12-24
NO313197B1 (no) 2002-08-26
MX9703146A (es) 1997-06-28
PT790994E (pt) 2002-08-30
CA2202992A1 (en) 1996-05-09
ES2173198T3 (es) 2002-10-16
DE69526668T2 (de) 2003-01-02
CN1161696A (zh) 1997-10-08
NZ293842A (en) 1998-09-24
JP3934678B2 (ja) 2007-06-20
JPH10508019A (ja) 1998-08-04
FI971831L (fi) 1997-04-29
FI971831A7 (fi) 1997-04-29
CA2202992C (en) 2003-05-13
HUT77174A (hu) 1998-03-02
IL115791A (en) 2000-09-28
FI971831A0 (fi) 1997-04-29
US6180786B1 (en) 2001-01-30
CN1068001C (zh) 2001-07-04
US5981553A (en) 1999-11-09
AU3638795A (en) 1996-05-23
DK0790994T3 (da) 2002-08-26
AU696423B2 (en) 1998-09-10
IL115791A0 (en) 1996-01-19
US5563157A (en) 1996-10-08

Similar Documents

Publication Publication Date Title
PT1193270E (pt) Pirrolobenzodiazepinas
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
ATE297203T1 (de) Antithrombotische mitteln
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
YU104690A (sh) Supstituisani imidazo-kondenzovani 6-člani heterocikli kao antagonisti angiotenzina 2
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
FI964815L (fi) Piperatsiinijohdoksia 5-HT1A antagonisteina
BR9914221B1 (pt) Derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos
CO4940466A1 (es) Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DK0696194T3 (da) Anvendelse af indolderivater som 5HT1-antagonister
FI972684A7 (fi) Piperidiinietikkahappojohdannaisia, joita voidaan käyttää fibrinogeeni antagonisteina
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
ATE375985T1 (de) Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
NO971991D0 (no) Heterosyklus-substituerte propensyrederivater som NMDA-antagonister
SE9504662D0 (sv) New compounds
SE9902387D0 (sv) New pharmaceutically active compounds
FI955604A7 (fi) 3-(indol-3-yyli)propenoiinihappojohdannaiset NMDA-antagonisteina
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
DK0888340T3 (da) 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-carboxylsyre-derivater som antagonister for enodthelin
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees